Pharmacological treatment in behavioural medicine: The importance of neurochemistry, molecular biology and mechanistic hypotheses

Veterinary Journal

Volumn 162, Issue 1, 2001, Pages 9-23

  Overall, Karen L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 HT; Brain derived neurotrophic factor (BDNF); Cytosolic response element binding protein (CREB); Gamma amino butyric acid (GABA); Norepinephrine (NE); Psychopharmacology; Selective serotonin re uptake inhibitor (SSRI); Serotonin; Synaptic plasticity; Tricyclic antidepressant (TCA)

Indexed keywords

4 AMINOBUTYRIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; NEUROTRANSMITTER; NORADRENALIN; PSYCHOTROPIC AGENT; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL BEHAVIOR; FOLLOW UP; LONG TERM POTENTIATION; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NONHUMAN; PSYCHOPHARMACOLOGY; REVIEW; VETERINARY MEDICINE;

ANIMALIA; FELIDAE;

EID: 0034931924     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1053/tvjl.2001.0568     Document Type: Review

References (55)

1. ALLGULANDER, C., CLONIGER, C. R., PRYZBECK, T. R. & BRANDT, L. (1997). Changes on the temperament and character inventory after paroxetine treatment in volunteers with generalized anxiety disorder. Psychopharmacology Bulletin 34, 165-6.
2. ALTEMUS, M., GLOWA, J. R. & MURPHY, D. L. (1993). Attenuation of food restriction-induced running by chronic fluoxetine treatment. Psychopharmacology Bulletin 29, 397-400.
3. ANANTH, J. (1986). Clomipramine: an anti-obsessive drug. Canadian Journal of Psychiatry 31, 253-8.
4. BLIER, P. & DE MONTIGNY, C. (1997). Current psychiatric uses of drugs acting on the serotonin system. In: Serotonergic Neurons and 5-HT Receptors in the CNS, eds. H. G. Baumgarten and M. Gothert, pp. 227-750. Berlin: Springer.
5. BROWN, T. M., SKOP, B. P. & MARETH, T. R. (1996). Pathophysiology and management of the serotonin syndrome. The Annals of Pharmacotherapy 30, 527-33.
6. CACCIA, S. & GARATTINI, S. (1992). Pharmacokinetic and pharmacodynamic significance of antidepressant drug metabolites. Pharmacology Research 26, 317-29.
7. CAPELLA, D., BRUGUERA, M., FIGUERAS, A. & LAPORTE, J. R. (1999). Fluoxetine-induced hepatitis: why is post-marketing surveillance needed? European Journal of Clinical Pharmacology 55, 545-6.
8. COOPER, G. L. (1988). The safety of fluoxetine - an update. British Journal of Psychiatry 153 [Suppl 3], 77-86.
9. DANIEL, H., LEVENES, C. & CRÉPEL, F. (1998). Cellular mechanisms of cerebellar LTD. Trends in Neuroscience 21, 401-7.
10. DEBOER, T., STOOF, J. C. & VAN DUIJN, H. (1982). The effects of convulsant and anticonvulsant drugs on the release of radio labeled GABA, glutamate, noradrenaline, serotonin, and acetylcholine from rat cortical slices. Brain Research 253, 153-60.
11. DODMAN, N. H., DONNELLY, R., SHUSTER, L., MERTENS, P. & MICZEK, K. (1996). Use of fluoxetine to treat dominance aggression in dogs. Journal of the American Veterinary Medical Association 209, 1585-7.
12. DUMAN, R. S. (1998). Novel therapeutic approaches beyond the serotonin receptor. Biological Psychiatry 44, 324-35.
13. DUMAN, R. S., HENINGER, G. R. & NESTLER, E. J. (1997). A molecular and cellular theory of depression. Archives of General Psychiatry 54, 597-606.
14. FLAMENT, M. F., RAPPOPORT, J. L. & BERG, C. J. (1985). Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Archives of General Psychiatry 42, 977-83.
15. GREENBLATT, D. J., SHADER, R. I., DIVOLL, M. & HARMATZ, J. S. (1981). Benzodiazepines: a summary of pharmacokinetic properties. British Journal of Pharmacology 11(Suppl), 11S-16S.
16. GREENBLATT, D. J., SHADER, R. I. & ABERNETHY, D. R. (1983). Drug-therapy: current status of benzodiazepines. New England Journal of Medicine 309, 344-58.
17. HART, B. L., ECKSTEIN, R. A., POWELL, K L. & DODMAN, N. H. (1993). Effectiveness of buspirone on urine spraying and inappropriate urination in cats. Journal of the American Veterinary Medical Association 203, 254-8.
18. HEWSON, C. J., CONLON, P. D., LUESCHER, U. A. & BALL, R. O. (1998a). The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. Journal of Veterinary Pharmacology and Therapy 21, 214-222.
19. HEWSON, C. J., LUESCHER, A., PARENT, J. M., CONLON, P. D. & BALL, R. O. (1998b). Efficacy of clomipramine in the treatment of canine compulsive disorder. Journal of the American Veterinary Medical Association 213, 1760-6.
20. HOLLAND, C. T. (1988). Successful long-term treatment of a dog with psychomotor seizures using carbamazepine. Australian Veterinary Journal 65, 389-92
21. HYMAN RAPAPORT, M., WOLKOW, R. M. & CLARY, C. M. (1998). Methodologies and outcomes from sertraline multicenter flexible-dose trials. Psychopharmacology Bulletin 32, 183-9.
22. KAPLAN, H. I. & SADOCK, B. J. (1993). Pocket Handbook of Psychiatric Drug Treatment. Baltimore: William and Wilkins.
23. KENNEDY, J. L., BRADWEJN, J., KOSZYCKI, D., KING, N., CROWE, R., VINCENT, J. & FOURIE, O. (1999). Investigation of cholecystokinin system genes in panic disorder. Molecular Psychiatry 4, 284-5.
24. KING, J. N., SIMPSON, B. S., OVERALL, K. L., APPLBY, D., PAGEAT, P., ROSS, C., CHAURAND, J. P., HEATH, S., BEATA, C., WEISS, A. B., MULLER, G., PARIS, T., BATAILLE, B. G., PARKER, J., PETIT, S. & WREN, J. (2000a). Treatment of separation anxiety in dogs with clomipramine: results from a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial. Journal of Applied Animal Behaviour Science 67, 255-75.
25. KING, J. N., MAURER, M. P., ALTMANN, B. & STREHLAU, G. (2000b). Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration. American Journal of Veterinary Research 61, 80-5.
26. LAUDER, J. M., LIU, J., DEVAUD, L. & MORROW, A. L. (1998). GABA as a trophic factor for developing monamine neurons. Perspectives in Developmental Neurobiology 5, 247-59.
27. MARDER, A. R. (1991). Psychotropic drugs and behavior therapy. Veterinary Clinics of North America: Small Animal Practice 21, 339-42.
28. MÅRTENSSON, E., AXELSSON, R., NYBERG, G. & SVENSSON, C. (1984). Pharmacokinetic properties of the antidepressant drugs amitriptyline, clomipramine, and imipramine: a clinical study. Current Therapy and Research 36, 228-38.
29. MCTAVISH, D. & BENFIELD, P. (1990). Clomipramine: an overview of its pharmacological properties and a review of its therapeutic use in obsessive-compulsive behavior and panic attack. Drug 39, 136-53.
30. MELTZER-BRODY, S., CONNOR, K. M., CHURCHILL, E. & DAVIDSON, J. R. T. (2000). Symptom-specific effects of fluoxetine in post-traumatic stress disorder. International Clinical Psychopharmacology 15, 227-31.
31. MOON-FANELLI, A. A. & DODMAN, N. H. (1998). Description and development of compulsive tail chasing in terriers and response to clomipramine treatment. Journal of the American Veterinary Medical Association 212, 1252-7.
32. NATTAL, S. & MITTLEMAN, M. (1984). Treatment of ventricular tachyarrhythmias resulting from amitriptyline toxicity in dogs. Journal of Pharmacology and Experimental Therapeutics 231, 430-5.
33. OVERALL, K. L. (1994). Use of clomipramine to treat ritualistic motor behavior in dogs. Journal of the American Veterinary Medical Association 205, 1733-41.
34. OVERALL K. L. (1997). Clinical Behavioral Medicine for Small Animals. St. Louis: Mosby.
35. OVERALL, K. L. (1998a). Diagnosing feline elimination disorders. Veterinary Medicine 93, 350-62.
36. OVERALL, K. L. (1998b). Tracing the roots of feline elimination disorders to aggression. Veterinary Medicine 93, 363-6.
37. OVERALL, K. L. (1998c). Treating feline elimination disorders. Veterinary Medicine 93, 367-82.
38. OVERALL, K. L. (1999a). Allow behavioral drugs ample time to take effect. Veterinary Medicine 94, 858-9.
39. OVERALL, K. L. (1999b). Understanding and treating dominance aggression: an overview. Veterinary Medicine 94, 976-9.
40. OVERALL, K. L. (1999c). Behavioral approaches to canine dominance aggression. Part IV. The addition of medication. Veterinary Medicine 94, 1049-1055.
41. OVERALL, K. L. (2000). Behavior modifying drugs: Neurochemistry and molecular biology. Proceedings of the 18th ACVIM Forum 18, 68-71.
42. PERSE, T. (1988). Obsessive-compulsive disorder: A treatment review. Journal of Clinical Psychiatry 49, 48-55.
43. POUCHELON, J. L., MARTEL, E., CHAMPEROUX, P., RICHARD, S. & KING, J. N. (2000). Effect of clomipramine hydrochloride on the electrocardiogram and heart rate of dogs. American Journal of Veterinary Research, in press.
44. REICH, M. R., OHAD, D. G., OVERALL, K. L. & DUNHAM, A. E. (2000). Electrocardiographic assessment of antianxiety medication in dogs and correlation with drug serum concentration. Journal of the American Veterinary Medical Association 216, 1571-5.
45. SALTER, M. W. (1998). Src, N-methyl-D-aspartate (NMDA) receptors, and synaptic plasticity. Biochemical Pharmacology 56, 789-98.
46. SCHWARTZ, M. A., KOECHLIN, B. A., POSTMA, E., PALMER, S. & KROL, G. (1965). Metabolism of diazepam in rat, dog, and man. Journal of Pharmacology and Experimental Therapy 149, 423-35.
47. SEKSEL, K. & LINDEMAN, M. J. (1998). Use of clomipramine in the treatment of anxiety-related and obsessive-compulsive disorders in cats. Australian Veterinary Journal 76, 317-21.
48. SINGH, L., LEWIS, A. S., FIELD, M. J., HUGHES, J. & WOODRUFF, G. N. (1991). Evidence for involvement of the brain cholecystokinin B receptor in anxiety. Proceedings of the National Academy of Science USA 88, 1130-3.
49. SOHN, R. S. & FERRENDELLI, J. A. (1976). Anticonvulsant drug mechanisms. Phenytoin, phenobarbital, and ethoxsuximide and calcium flux in isolated presynaptic endings. Archives of Neurology 33, 626-9.
50. TAUBØLL, E. & GJERSTAD, L. (1993). Comparison of 5 α-pregnan-3α-01-20-one and phenobarbital on cortical synaptic activation and inhibition studied in vitro. Epilepsia 34, 228-35.
51. THOREN, P., ASBERG, M. & CRONHOLM, B. (1980). Clomipramine treatment of obsessive-compulsive disorder. Archives of General Psychiatry 37, 1281-5.
52. TROTTI, D., DANBOLDT, N. C. & VOLTERRA, A. (1998). Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration. Trends in Pharmacological Sciences 19, 328-34.
53. WAAGEPETERSEN, H. S., SONNEWALD, U. & SCHOUSBOE, A. (1999). The GABA paradox: multiple roles as metabolite, neurotransmitter, and neurodifferentiative agents. Journal of Neurochemistry 73, 1335-42.
54. WIERSMA, J., HONIG, A. & PETERS, F. P. J. (2000). Clomipramine-induced allergic hepatitis: a case report. International Journal of Psychiatry in Clinical Practice 4, 69-71.
55. YOKOTA, S., ISHIKURA, Y. & ONO, H. (1987). Cardiovascular effects of paroxetine, a newly developed antidepressant, in anesthetized dogs in comparison with those of imipramine, amitriptyline and clomipramine. Japanese Journal of Pharmacology 45, 335-42.